Skip to main content
Fig. 6 | BMC Neurology

Fig. 6

From: FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide

Fig. 6

Kaplan–Meier curves for overall survival of different FXYD2 mRNA expression in TCGA and REMBRANDT databases. The Kaplan–Meier curves for overall survival of different FXYD2 mRNA expression in glioma patients with different WHO grade (A, C, E) in TCGA. The Kaplan–Meier curves for overall survival of different FXYD2 mRNA expression in glioma patients with different WHO grade (B, D, F) in REMBRANDT. Log rank test was used to compare the difference between the two survival curves

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us